Medistim delivered the best year yet, setting a new all-time high for sales, reaching MNOK 491.9 in revenues for the year. In addition to delivering on this ever-so-important goal of continued growth in both Cardiac bypass and Vascular surgery, we had a tremendous year for Imaging product growth.
Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build and strengthen our position in the Vascular segment. In 2022, we ended up at MNOK 69.5 in vascular product revenues, growing at 27.3 %.